

CLIENT'S NAME AND ADDRESS:
ACROFEMI HEALTHCARE LTD (MEDIWHEEL)
F-703, F-703, LADO SARAI, MEHRAULI
SOUTH WEST DELHI

SOUTH WEST DELHI NEW DELHI 110030 DELHI INDIA 8800465156 SRL Ltd

S.K. Tower, Hari Niwas, LBS Marg

THANE, 400602 MAHARASHTRA, INDIA

Tel: 9111591115, Fax: CIN - U74899PB1995PLC045956

Email: customercare.thane@srl.in

PATIENT NAME: ARVIND PANDIT MALI

PATIENT ID : **ARVIM161278181**

ACCESSION NO: **0181VC001353** AGE: 43 Years SEX: Male

DRAWN: RECEIVED: 30/03/2022 09:56 REPORTED: 01/04/2022 12:50

REFERRING DOCTOR: SELF CLIENT PATIENT ID:

| Test Report Status <u>Final</u> | Results | Biological Reference Interval Units | |
|---------------------------------|---------|-------------------------------------|--|
|---------------------------------|---------|-------------------------------------|--|

MEDI WHEEL FULL BODY HEALTH CHECK UP ABOVE 40 MALE

| BLOOD COUNTS,EDTA WHOLE BLOOD | | | | |
|---|---------|------|--------------|----------|
| HEMOGLOBIN | 14.4 | | 13.0 - 17.0 | g/dL |
| METHOD: SLS- HEMOGLOBIN DETECTION METHOD | | | | |
| RED BLOOD CELL COUNT | 5.34 | | 4.5 - 5.5 | mil/µL |
| METHOD: HYDRODYNAMIC FOCUSING BY DC DETECTION | | | | |
| WHITE BLOOD CELL COUNT | 7.03 | | 4.0 - 10.0 | thou/µL |
| METHOD: FLUORESCENCE FLOW CYTOMETRY | | | | |
| PLATELET COUNT | 149 | Low | 150 - 410 | thou/µL |
| METHOD: HYDRODYNAMIC FOCUSING BY DC DETECTION | | | | |
| RBC AND PLATELET INDICES | | | | |
| HEMATOCRIT | 43.1 | | 40.0 - 50.0 | % |
| METHOD: CUMULATIVE PULSE HEIGHT DETECTION METHOD | | | | |
| MEAN CORPUSCULAR VOL | 80.7 | Low | 83.0 - 101.0 | fL |
| METHOD: CALCULATED FROM RBC & HCT | | | | |
| MEAN CORPUSCULAR HGB. | 27.0 | | 27.0 - 32.0 | pg |
| METHOD: CALCULATED FROM THE RBC & HGB | | | | |
| MEAN CORPUSCULAR HEMOGLOBIN | 33.4 | | 31.5 - 34.5 | g/dL |
| CONCENTRATION METHOD: CALCULATED FROM THE HGB & HCT | | | | |
| MENTZER INDEX | 15.1 | | | |
| RED CELL DISTRIBUTION WIDTH | 13.1 | | 11.6 - 14.0 | % |
| METHOD : CALCULATED FROM RBC SIZE DISTRIBUTION CURVE | 13.1 | | 11.0 - 14.0 | 70 |
| MEAN PLATELET VOLUME | 13.1 | High | 6.8 - 10.9 | fL |
| METHOD : CALCULATED FROM PLATELET COUNT & PLATELET HEMA | _ | 9 | 0.0 10.9 | 16 |
| WBC DIFFERENTIAL COUNT - NLR | (TOCKIT | | | |
| SEGMENTED NEUTROPHILS | 62 | | 40 - 80 | % |
| METHOD : FLOW CYTOMETRY WITH LIGHT SCATTERING | 02 | | 40 - 80 | 90 |
| ABSOLUTE NEUTROPHIL COUNT | 4.36 | | 2.0 - 7.0 | thou/µL |
| METHOD : FLOW CYTOMETRY WITH LIGHT SCATTERING | 4.30 | | 2.0 - 7.0 | tilou/μL |
| LYMPHOCYTES | 30 | | 20 - 40 | % |
| METHOD: FLOW CYTOMETRY WITH LIGHT SCATTERING | 30 | | 20 - 40 | 70 |
| ABSOLUTE LYMPHOCYTE COUNT | 2.11 | | 1.0 - 3.0 | thou/µL |
| METHOD : FLOW CYTOMETRY WITH LIGHT SCATTERING | 2.11 | | 1.0 - 3.0 | tilou/µL |
| | 2.1 | | | |
| NEUTROPHIL LYMPHOCYTE RATIO (NLR) | | | 1 6 | 0/ |
| EOSINOPHILS | 03 | | 1 - 6 | % |
| METHOD : FLOW CYTOMETRY WITH LIGHT SCATTERING | | | | |





CLIENT'S NAME AND ADDRESS:
ACROFEMI HEALTHCARE LTD (MEDIWHEEL)
F-703, F-703, LADO SARAI, MEHRAULI
SOUTH WEST DELHI
NEW DELHI 110030

ACCESSION NO: **0181VC001353**

DELHI INDIA

8800465156

SRL Ltd

S.K. Tower, Hari Niwas, LBS Marg

THANE, 400602 MAHARASHTRA, INDIA

Tel: 9111591115, Fax: CIN - U74899PB1995PLC045956

PATIENT ID:

ARVIM161278181

Email: customercare.thane@srl.in

PATIENT NAME: ARVIND PANDIT MALI

AGE: 43 Years SEX: Male

RECEIVED: 30/03/2022 09:56 REPORTED: 01/04/2022 12:50 DRAWN:

REFERRING DOCTOR: SELF CLIENT PATIENT ID:

| Test Report Status | <u>Final</u> | Results | | Biological Reference Inter | val Units |
|------------------------|--------------------------------------|--------------------------|-----------|--|------------|
| ADCOLUTE FOCIMODU | TI COUNT | 0.24 | | 0.02. 0.50 | |
| ABSOLUTE EOSINOPH: | IL COUNT RY WITH LIGHT SCATTERING | 0.21 | | 0.02 - 0.50 | thou/µL |
| MONOCYTES | VI WITH LIGHT SCATTLKING | 05 | | 2 - 10 | % |
| | RY WITH LIGHT SCATTERING | 03 | | 2 10 | 70 |
| ABSOLUTE MONOCYTE | COUNT | 0.35 | | 0.2 - 1.0 | thou/µL |
| METHOD : FLOW CYTOMETE | RY WITH LIGHT SCATTERING | | | | |
| DIFFERENTIAL COUNT | PERFORMED ON: | EDTA SMEAR | | | |
| MORPHOLOGY | | | | | |
| RBC | | PREDOMINANTL | Y NORMOC | YTIC NORMOCHROMIC | |
| WBC | | NORMAL MORPH | HOLOGY | | |
| METHOD : MICROSCOPIC E | XAMINATION | | | | |
| PLATELETS | | ADEQUATE,PLAT THOU/uL | TELET COU | NT ON SMEAR APPEARS TO BE | 140-150 |
| ERYTHRO SEDIMENT | TATION RATE, BLOOD | | | | |
| SEDIMENTATION RATE | E (ESR) | 04 | | 0 - 14 | mm at 1 hr |
| METHOD: WESTERGREN M | ETHOD | | | | |
| GLYCOSYLATED HEM | IOGLOBIN, EDTA WH | OLE BLOOD | | | |
| GLYCOSYLATED HEMO | GLOBIN (HBA1C) | 6.1 | High | Non-diabetic: < 5.7 Pre-diabetics: 5.7 - 6.4 Diabetics: > or = 6.5 ADA Target: 7.0 Action suggested: > 8.0 | % |
| METHOD : HPLC | | | | | |
| MEAN PLASMA GLUCO | | 128.4 | High | < 116.0 | mg/dL |
| METHOD : CALCULATED PA | | | | | |
| GLUCOSE, FASTING, | | 79 | | 74.0 - 106.0 | ma/dl |
| GLUCOSE, FASTING, F | | 79 | | 74.0 - 106.0 | mg/dL |
| GLUCOSE, POST-PRA | ANDIAL, PLASMA | | | | |
| GLUCOSE, POST-PRAN | IDIAL, PLASMA | 90 | | 74 - 140 | mg/dL |
| METHOD : GLUCOSE OXIDA | ASE | | | | |
| CORONARY RISK PR | OFILE (LIPID PROFI | LE), SERUM. | | | |
| CHOLESTEROL | | 111 | | < 200 Desirable 200 - 239 Borderline High >/= 240 High | mg/dL |
| METHOD : CHOLESTEROL C | OXIDASE | | | | |
| TRIGLYCERIDES | | 77 | | Normal: <150 Borderline high: 150 - 199 High: 200 - 499 Very high: > or = 500 | mg/dL |
| METHOD : ENZYMATIC ASS | AY | | | , 5 | |

METHOD: ENZYMATIC ASSAY







CLIENT'S NAME AND ADDRESS:
ACROFEMI HEALTHCARE LTD (MEDIWHEEL)
F-703, F-703, LADO SARAI, MEHRAULI
SOUTH WEST DELHI
NEW DELHI 110030

DELHI INDIA 8800465156 SRL Ltd

S.K. Tower, Hari Niwas, LBS Marg

THANE, 400602 MAHARASHTRA, INDIA

Tel: 9111591115, Fax: CIN - U74899PB1995PLC045956

Email: customercare.thane@srl.in

PATIENT NAME: ARVIND PANDIT MALI

PATIENT ID: ARVIM161278181

ACCESSION NO: **0181VC001353** AGE: 43 Years SEX: Male

RECEIVED: 30/03/2022 09:56 REPORTED: 01/04/2022 12:50 DRAWN:

REFERRING DOCTOR: SELF CLIENT PATIENT ID:

| Test Report Status <u>Final</u> | Results | | Biological Reference Interva | al Units |
|--|---------|-----|--|-------------|
| HDL CHOLESTEROL | 32 | Low | < 40 Low | mg/dL |
| METHOD : DIRECT- NON IMMUNOLOGICAL | | | >/=60 High | |
| DIRECT LDL CHOLESTEROL | 64 | | < 100 Optimal 100 - 129 Near or above optim 130 - 159 Borderline High 160 - 189 High >/= 190 Very High | mg/dL al |
| METHOD: ENZYMATIC ASSAY | | | , 150 tel, ligi | |
| NON HDL CHOLESTEROL | 79 | | | mg/dL |
| METHOD: CALCULATED PARAMETER | | | | |
| CHOL/HDL RATIO | 3.0 | Low | 3.3- 4.4 Low Risk 4.5 -7.0 Average Risk 7.1 -11.0 Moderate Risk > 11.0 High Risk | |
| METHOD: CALCULATED PARAMETER | | | | |
| LDL/HDL RATIO | 2.0 | | 0.5 - 3.0 Desirable/Low Risk 3.1 - 6.0 Borderline/Moderate Risk >6.0 High Risk | |
| METHOD: CALCULATED PARAMETER | 45.0 | | 10.05 | |
| VERY LOW DENSITY LIPOPROTEIN | 15.0 | | 10 - 35 | mg/dL |
| METHOD : CALCULATED PARAMETER | | | | |
| LIVER FUNCTION PROFILE, SERUM | 0.62 | | 0.2 1.2 | no a /all |
| BILIRUBIN, TOTAL METHOD: DIPHYLLINE DIAZONIUM SALTS | 0.63 | | 0.2 - 1.3 | mg/dL |
| BILIRUBIN, DIRECT METHOD: DIPHYLLINE DIAZONIUM SALTS | 0.10 | | 0.0 - 0.3 | mg/dL |
| BILIRUBIN, INDIRECT METHOD: DIPHYLLINE DIAZONIUM SALTS | 0.53 | | 0.0 - 1.1 | mg/dL |
| TOTAL PROTEIN | 7.5 | | 6.3 - 8.3 | g/dL |
| ALBUMIN | 4.6 | | 3.5 - 5.0 | g/dL |
| GLOBULIN | 2.9 | | 2.0 - 3.5 | g/dL |
| ALBUMIN/GLOBULIN RATIO | 1.6 | | 1.0 - 2.0 | RATIO |
| ASPARTATE AMINOTRANSFERASE (AST/SGOT) | 33 | | 17 - 59 | U/L |
| | 23 | | < 50.0 | |
| ALANINE AMINOTRANSFERASE (ALT/SGPT) ALKALINE PHOSPHATASE | | | | U/L |
| | 87 | | 38 - 126 | U/L |
| GAMMA GLUTAMYL TRANSFERASE (GGT) | 21 | | 15 - 73 | U/L |
| LACTATE DEHYDROGENASE | 233 | | 120 - 246 | U/L |
| SERUM BLOOD UREA NITROGEN | _ | _ | | |
| BLOOD UREA NITROGEN | 7 | Low | 9.0 - 20.0 | mg/dL |







CLIENT'S NAME AND ADDRESS:
ACROFEMI HEALTHCARE LTD (MEDIWHEEL)
F-703, F-703, LADO SARAI, MEHRAULI
SOUTH WEST DELHI
NEW DELHI 110030

DELHI INDIA

8800465156

SRL Ltd

S.K. Tower, Hari Niwas, LBS Marg

THANE, 400602 MAHARASHTRA, INDIA

Tel: 9111591115, Fax: CIN - U74899PB1995PLC045956

PATIENT ID:

ARVIM161278181

Email: customercare.thane@srl.in

PATIENT NAME: ARVIND PANDIT MALI

ACCESSION NO: **0181VC001353** AGE: 43 Years SEX: Male

RECEIVED: 30/03/2022 09:56 REPORTED: 01/04/2022 12:50 DRAWN:

REFERRING DOCTOR: SELF CLIENT PATIENT ID:

| Test Report Status | <u>Final</u> | Results | Biological Reference I | nterval Units |
|-----------------------------------|----------------------|--------------|------------------------|---------------|
| METHOD : UREASE WITH IN | DICATOR DYF | | | |
| CREATININE, SERUM | | | | |
| CREATININE | | 0.94 | 0.66 - 1.25 | mg/dL |
| METHOD : ENZYMETIC IDMS | 3 | | | 5, == |
| BUN/CREAT RATIO | | | | |
| BUN/CREAT RATIO | | 7.45 | | |
| URIC ACID, SERUM | | | | |
| URIC ACID | | 4.8 | 3.5 - 8.5 | mg/dL |
| METHOD : URICASE UV | | | | <u>-</u> - |
| TOTAL PROTEIN, SER | RUM | | | |
| TOTAL PROTEIN | | 7.5 | 6.3 - 8.30 | g/dL |
| METHOD : BIURET, END POI | NT | | | |
| ALBUMIN, SERUM | | | | |
| ALBUMIN | | 4.6 | 3.5 - 5.0 | g/dL |
| METHOD : BCG DYE BINDIN | G METHOD | | | |
| GLOBULIN | | | | |
| GLOBULIN | | 2.9 | 2.0 - 3.5 | g/dL |
| METHOD : CALCULATED PAR | | | | |
| ELECTROLYTES (NA/ | K/CL), SERUM | | | |
| SODIUM | | 143 | 137 - 145 | mmol/L |
| METHOD : ION SELECTIVE E | LECTRODE TECHNOLOGY | | | |
| POTASSIUM | | 4.0 | 3.6 - 5.0 | mmol/L |
| METHOD : ION SELECTIVE E | ELECTRODE TECHNOLOGY | 104 | 98 - 107 | |
| CHLORIDE METHOD: ION SELECTIVE E | I ECTRODE TECHNOLOGY | 104 | 98 - 107 | mmol/L |
| URINALYSIS | LECTRODE TECHNOLOGY | | | |
| COLOR | | PALE YELLOW | | |
| METHOD : VISUAL INSPECTI | ION | TALL TELLOW | | |
| APPEARANCE | | CLEAR | | |
| METHOD : VISUAL INSPECTI | ION | | | |
| PH | | 6.0 | 4.7 - 7.5 | |
| METHOD : DOUBLE INDICAT | OR PRINCIPLE | | | |
| SPECIFIC GRAVITY | | 1.005 | 1.003 - 1.035 | |
| METHOD: IONIC CONCENTE | RATION METHOD | | | |
| GLUCOSE | | NOT DETECTED | NOT DETECTED | |
| METHOD : GLUCOSE OXIDAS | SE PEROXIDASE | | | |
| PROTEIN | | NOT DETECTED | NOT DETECTED | |







CLIENT'S NAME AND ADDRESS:
ACROFEMI HEALTHCARE LTD (MEDIWHEEL)
F-703, F-703, LADO SARAI, MEHRAULI
SOUTH WEST DELHI
NEW DELHI 110030

DELHI INDIA 8800465156 SRL Ltd

S.K. Tower, Hari Niwas, LBS Marg

THANE, 400602 MAHARASHTRA, INDIA

Tel: 9111591115, Fax: CIN - U74899PB1995PLC045956

Email: customercare.thane@srl.in

PATIENT ID: **PATIENT NAME: ARVIND PANDIT MALI** ARVIM161278181

ACCESSION NO: 0181VC001353 AGE: 43 Years SEX: Male

RECEIVED: 30/03/2022 09:56 REPORTED: 01/04/2022 12:50 DRAWN:

REFERRING DOCTOR: SELF CLIENT PATIENT ID:

| Test Report Status <u>Final</u> | Results | Biological Reference Interva | al Units |
|---|-----------------------|------------------------------|----------|
| | | | |
| METHOD: TETRA BROMOPHENOL BLUE/SULFOSALICYLIC ACID | | | |
| KETONES | NOT DETECTED | NOT DETECTED | |
| METHOD: NITROPRUSSIDE REACTION | | | |
| BLOOD | NOT DETECTED | NOT DETECTED | |
| METHOD: PEROXIDASE | | | |
| UROBILINOGEN | NORMAL | NORMAL | |
| METHOD: MODIFIED EHRLICH REACTION | | | |
| NITRITE | NOT DETECTED | NOT DETECTED | |
| METHOD: 1,2,3,4-TETRAHYDROBENZO(H)QUINOLIN-3-OL | | | |
| PUS CELL (WBC'S) | 1-2 | 0-5 | /HPF |
| METHOD: MICROSCOPIC EXAMINATION | | | |
| EPITHELIAL CELLS | 0-1 | 0-5 | /HPF |
| METHOD: MICROSCOPIC EXAMINATION | | | |
| ERYTHROCYTES (RBC'S) | NOT DETECTED | NOT DETECTED | /HPF |
| METHOD: MICROSCOPIC EXAMINATION | | | |
| CASTS | NOT DETECTED | | |
| METHOD: MICROSCOPIC EXAMINATION | | | |
| CRYSTALS | NOT DETECTED | | |
| METHOD: MICROSCOPIC EXAMINATION | | | |
| BACTERIA | NOT DETECTED | NOT DETECTED | |
| METHOD: MICROSCOPIC EXAMINATION | | | |
| THYROID PANEL, SERUM | | | |
| T3 | 126.8 | 58 - 159 | ng/dL |
| METHOD: CHEMILUMINESCENT MICROPARTICLE IMMUNO ASSAY | | | |
| T4 | 7.20 | 4.87 - 11.71 | μg/dL |
| METHOD: CHEMILUMINESCENT MICROPARTICLE IMMUNO ASSAY | | | |
| TSH 3RD GENERATION | 1.089 | 0.350 - 4.940 | μIU/mL |
| METHOD: CHEMILUMINESCENT MICROPARTICLE IMMUNO ASSAY | | | |
| ABO GROUP & RH TYPE, EDTA WHOLE BLOOD | | | |
| ABO GROUP | TYPE B | | |
| METHOD : GEL COLUMN AGGLUTINATION METHOD. | | | |
| RH TYPE | POSITIVE | | |
| METHOD : GEL COLUMN AGGLUTINATION METHOD. | | | |
| XRAY-CHEST | | | |
| IMPRESSION | NO ABNORMALITY DETECT | TED | |
| TMT OR ECHO | | | |
| TMT OR ECHO | CONCENTRIC LVH | | |



ECG

Page 5 Of 12 Scan to View Report



ACROFEMI HEALTHCARE LTD (MEDIWHEEL)

F-703, F-703, LADO SARAI, MEHRAULI

ACCESSION NO: 0181VC001353

SOUTH WEST DELHT **NEW DELHI 110030**

DELHI INDIA 8800465156

S.K. Tower, Hari Niwas, LBS Marg

THANE, 400602 MAHARASHTRA, INDIA

Tel: 9111591115, Fax: CIN - U74899PB1995PLC045956

PATIENT ID:

ARVIM161278181

Email: customercare.thane@srl.in

PATIENT NAME: ARVIND PANDIT MALI

RECEIVED: 30/03/2022 09:56 DRAWN: REPORTED: 01/04/2022 12:50

REFERRING DOCTOR: SELF CLIENT PATIENT ID:

Test Report Status Results **Biological Reference Interval** Units <u>Final</u>

SEX: Male

ECG WITHIN NORMAL LIMITS

MEDICAL HISTORY

RELEVANT PRESENT HISTORY HYPERTENSION SINCE 2.5 YEARS

AGE: 43 Years

C/O CHEST DISCOMFORT ON EXERTION.

NOT SIGNIFICANT RELEVANT PAST HISTORY

RELEVANT PERSONAL HISTORY MARRIED / 2 CHILD / MIXED DIET / NO ALLERGIES / NO SMOKING /

OCC. ALCOHOL.

RELEVANT FAMILY HISTORY NOT SIGNIFICANT

HISTORY OF MEDICATIONS TAB: - TELMA / ATORVA / ECOSPRIN

ANTHROPOMETRIC DATA & BMI

HEIGHT IN METERS 1.80 mts WEIGHT IN KGS. 99 Kgs

BMI 31 BMI & Weight Status as follows: kg/sqmts Below 18.5: Underweight

18.5 - 24.9: Normal 25.0 - 29.9: Overweight 30.0 and Above: Obese

GENERAL EXAMINATION

MENTAL / EMOTIONAL STATE **NORMAL** PHYSICAL ATTITUDE **NORMAL** GENERAL APPEARANCE / NUTRITIONAL STATUS **OBESE BUILT / SKELETAL FRAMEWORK AVERAGE** FACIAL APPEARANCE NORMAL SKIN **NORMAL** UPPER LIMB **NORMAL** LOWER LIMB **NORMAL NECK NORMAL**

NECK LYMPHATICS / SALIVARY GLANDS NOT ENLARGED OR TENDER

THYROID GLAND **NOT ENLARGED**

CAROTID PULSATION **NORMAL TEMPERATURE NORMAL**

PULSE 80/MIN.REGULAR, ALL PERIPHERAL PULSES WELL FELT, NO CAROTID

BRUIT

RESPIRATORY RATE **NORMAL**

CARDIOVASCULAR SYSTEM

110/70 MM HG BP mm/Hq

(SUPINE)

PERICARDIUM NORMAL







ACROFEMI HEALTHCARE LTD (MEDIWHEEL) F-703, F-703, LADO SARAI, MEHRAULI SOUTH WEST DELHI

NEW DELHI 110030

DELHI INDIA 8800465156 SRL Ltd

S.K. Tower, Hari Niwas, LBS Marg

THANE, 400602 MAHARASHTRA, INDIA

Tel: 9111591115, Fax: CIN - U74899PB1995PLC045956

Email: customercare.thane@srl.in

PATIENT NAME: ARVIND PANDIT MALI PATIENT ID: ARVIM161278181

ACCESSION NO: 0181VC001353 AGE: 43 Years SEX: Male

01/04/2022 12:50 RECEIVED: 30/03/2022 09:56 DRAWN: REPORTED:

| REFERRING DOCTOR: SELF | CLIENT PATIENT ID : | | | |
|---------------------------------|---------------------|---------------------------------|-------|--|
| Test Report Status <u>Final</u> | Results | Biological Reference Interval (| Jnits | |
| | | | | |
| APEX BEAT | NORMAL | | | |
| HEART SOUNDS | NORMAL | | | |
| MURMURS | ABSENT | | | |
| RESPIRATORY SYSTEM | | | | |
| SIZE AND SHAPE OF CHEST | NORMAL | | | |
| MOVEMENTS OF CHEST | SYMMETRICAL | | | |
| BREATH SOUNDS INTENSITY | NORMAL | | | |
| BREATH SOUNDS QUALITY | VESICULAR (NORMAL) | | | |
| ADDED SOUNDS | ABSENT | | | |
| PER ABDOMEN | | | | |
| APPEARANCE | NORMAL | | | |
| VENOUS PROMINENCE | ABSENT | | | |
| LIVER | NOT PALPABLE | | | |
| SPLEEN | NOT PALPABLE | | | |
| HERNIA | ABSENT | | | |
| CENTRAL NERVOUS SYSTEM | | | | |
| HIGHER FUNCTIONS | NORMAI | | | |

NORMAL

NORMAL

HIGHER FUNCTIONS NORMAL CRANIAL NERVES **NORMAL** CEREBELLAR FUNCTIONS NORMAL SENSORY SYSTEM **NORMAL** MOTOR SYSTEM **NORMAL REFLEXES** NORMAL **MUSCULOSKELETAL SYSTEM**

JOINTS BASIC EYE EXAMINATION

SPINE

CONJUNCTIVA **NORMAL EYELIDS NORMAL** EYE MOVEMENTS **NORMAL CORNEA NORMAL**

DISTANT VISION RIGHT EYE WITHOUT GLASSES

REDUCED VISUAL ACUITY 6/9 DISTANT VISION LEFT EYE WITHOUT GLASSES REDUCED VISUAL ACUITY 6/9 NEAR VISION RIGHT EYE WITHOUT GLASSES REDUCED VISUAL ACUITY N/8 NEAR VISION LEFT EYE WITHOUT GLASSES REDUCED VISUAL ACUITY N/12







ACROFEMI HEALTHCARE LTD (MEDIWHEEL)

F-703, F-703, LADO SARAI, MEHRAULI

ACCESSION NO: 0181VC001353

SOUTH WEST DELHI **NEW DELHI 110030**

DELHI INDIA 8800465156

S.K. Tower, Hari Niwas, LBS Marg

THANE, 400602 MAHARASHTRA, INDIA

Tel: 9111591115, Fax: CIN - U74899PB1995PLC045956

PATIENT ID:

ARVIM161278181

Email: customercare.thane@srl.in

PATIENT NAME: ARVIND PANDIT MALI

RECEIVED: 30/03/2022 09:56 DRAWN: REPORTED: 01/04/2022 12:50

REFERRING DOCTOR: SFLF CLIENT PATIENT ID:

AGE: 43 Years

Test Report Status Results **Biological Reference Interval** Units <u>Final</u>

SEX: Male

COLOUR VISION NORMAL 17/15

SUMMARY

RELEVANT HISTORY NOT SIGNIFICANT RELEVANT GP EXAMINATION FINDINGS OBESE:- BMI 31 RELEVANT LAB INVESTIGATIONS HBA1C:-6.1 HDL:-32 RELEVANT NON PATHOLOGY DIAGNOSTICS ECG: - NORMAL.

X-RAY:- NORMAL.

2D ECHO: - CONCENTRIC LVH.

USG:- GRADE I FATTY LIVER. GALL BLADDER POLYP.

REMARKS / RECOMMENDATIONS

1)LOW FAT, LOW CARBOHYDRATE, HIGH FIBRE DIET.

2) REGULAR EXERCISE, REGULAR WALK FOR 30-40 MIN DAILY. 3) REPEAT BLOOD SUGAR AFTER 3 MONTHS OF DIET AND EXERCISE. 4)OPHTHALMOLOGY CONSULT FOR REDUCED VISUAL ACUITY. 5) ANNUAL USG ABDOMEN TO MONITOR GALL BLADDER POLYP.

6)SUGGEST TMT IN VIEW OF SYMPTOMS.

Interpretation(s)

BLOOD COUNTS, EDTA WHOLE BLOODThe cell morphology is well preserved for 24hrs. However after 24-48 hrs a progressive increase in MCV and HCT is observed leading to a decrease in MCHC. A direct smear is recommended for an accurate differential count and for examination of RBC morphology RBC AND PLATELET INDICES-

Mentzer index (MCV/RBC) is an automated cell-counter based calculated screen tool to differentiate cases of Iron deficiency anaemia(>13) from Beta thalassaemia trait (<13) in patients with microcytic anaemia. This needs to be interpreted in line with clinical correlation and suspicion. Estimation of HbA2 remains the gold standard for diagnosing a case of beta thalassaemia trait.

WBC DIFFERENTIAL COUNT - NLRThe optimal threshold of 3.3 for NLR showed a prognostic possibility of clinical symptoms to change from mild to severe in COVID positive patients. When age = 49.5 years old and NLR = 3.3, 46.1% COVID-19 patients with mild disease might become severe. By contrast, when age < 49.5 years old and NLR < 3.3, COVID-19 patients tend to show mild disease.

(Reference to - The diagnostic and predictive role of NLR, d-NLR and PLR in COVID-19 patients; A.-P. Yang, et al.; International Immunopharmacology 84 (2020) 106504 This ratio element is a calculated parameter and out of NABL scope. ERYTHRO SEDIMENTATION RATE, BLOOD-

Erythrocyte sedimentation rate (ESR) is a non - specific phenomena and is clinically useful in the diagnosis and monitoring of disorders associated with an increased production of acute phase reactants. The ESR is increased in pregnancy from about the 3rd month and returns to normal by the 4th week post partum. ESR is influenced by age, sex, menstrual cycle and drugs (eg. corticosteroids, contraceptives). It is especially low (0 -1mm) in polycythaemia, hypofibrinogenemia or congestive cardiac failure and when there are abnormalities of the red cells such as poikilocytosis, spherocytosis or sickle cells.

- 1. Nathan and Oski's Haematology of Infancy and Childhood, 5th edition
 2. Paediatric reference intervals. AACC Press, 7th edition. Edited by S. Soldin
 3. The reference for the adult reference range is "Practical Haematology by Dacie and Lewis, 10th Edition" GLYCOSYLATED HEMOGLOBIN, EDTA WHOLE BLOOD-

Glycosylated hemoglobin (GHb) has been firmly established as an index of long-term blood glucose concentrations and as a measure of the risk for the development of complications in patients with diabetes mellitus. Formation of GHb is essentially irreversible, and the concentration in the blood depends on both the life span of the red blood cell (average 120 days) and the blood glucose concentration. Because the rate of formation of GHb is directly proportional to the concentration of glucose in the blood, the GHb concentration represents the integrated values for glucose over the preceding 6-8 weeks.

Any condition that alters the life span of the red blood cells has the potential to alter the GHb level. Samples from patients with hemolytic anemias will exhibit decreased

glycated hemoglobin values due to the shortened life span of the red cells. This effect will depend upon the severity of the anemia. Samples from patients with polycythemia







ACROFEMI HEALTHCARE LTD (MEDIWHEEL) F-703, F-703, LADO SARAI, MEHRAULI

SOUTH WEST DELHI **NEW DELHI 110030** DELHI INDIA 8800465156

SRL Ltd

S.K. Tower, Hari Niwas, LBS Marg

THANE, 400602 MAHARASHTRA, INDIA

Tel: 9111591115, Fax: CIN - U74899PB1995PLC045956

Email: customercare.thane@srl.in

PATIENT NAME: ARVIND PANDIT MALI

PATIENT ID:

ARVIM161278181

ACCESSION NO: 0181VC001353 AGE: 43 Years SEX: Male

DRAWN: RECEIVED: 30/03/2022 09:56 REPORTED: 01/04/2022 12:50

REFERRING DOCTOR: SFLF CLIENT PATIENT ID:

Test Report Status Results **Biological Reference Interval** Units <u>Final</u>

or post-splenectomy may exhibit increased glycated hemoglobin values due to a somewhat longer life span of the red cells.

Glycosylated hemoglobins results from patients with HbSS, HbCC, and HbSC and HbD must be interpreted with caution, given the pathological processes, including anemia, increased red cell turnover, transfusion requirements, that adversely impact HbA1c as a marker of long-term glycemic control. In these conditions, alternative forms of testing such as glycated serum protein (fructosamine) should be considered.
"Targets should be individualized; More or less stringent glycemic goals may be appropriate for individual patients. Goals should be individualized based on duration of

diabetes, age/life expectancy, comorbid conditions, known CVD or advanced microvascular complications, hypoglycemia unawareness, and individual patient considerations.

References

- 1. Tietz Textbook of Clinical Chemistry and Molecular Diagnostics, edited by Carl A Burtis, Edward R.Ashwood, David E Bruns, 4th Edition, Elsevier publication, 2006,
- 2. Forsham PH. Diabetes Mellitus: A rational plan for management, Postgrad Med 1982, 71,139-154.
- 3. Mayer TK, Freedman ZR: Protein glycosylation in Diabetes Mellitus: A review of laboratory measurements and their clinical utility. Clin Chim Acta 1983, 127, 147-184. GLUCOSE, FASTING, PLASMA-

ADA 2021 guidelines for adults, after 8 hrs fasting is as follows:

Pre-diabetics: 100 - 125 mg/dL Diabetic: > or = 126 mg/dL

GLUCOSE, POST-PRANDIAL, PLASMA-ADA Guidelines for 2hr post prandial glucose levels is only after ingestion of 75grams of glucose in 300 ml water, over a period of 5 minutes.

CORONARY RISK PROFILE (LIPID PROFILE), SERUM-

Serum cholesterol is a blood test that can provide valuable information for the risk of coronary artery disease This test can help determine your risk of the build up of plaques in your arteries that can lead to narrowed or blocked arteries throughout your body (atherosclerosis). High cholesterol levels usually don't cause any signs or symptoms, so a cholesterol test is an important tool. High cholesterol levels often are a significant risk factor for heart disease and important for diagnosis of hyperlipoproteinemia, atherosclerosis, hepatic and thyroid diseases.

Serum Triglyceride are a type of fat in the blood. When you eat, your body converts any calories it doesn't need into triglycerides, which are stored in fat cells. High triglyceride levels are associated with several factors, including being overweight, eating too many sweets or drinking too much alcohol, smoking, being sedentary, or having diabetes with elevated blood sugar levels. Analysis has proven useful in the diagnosis and treatment of patients with diabetes mellitus, nephrosis, liver obstruction, other diseases involving lipid metabolism, and various endocrine disorders. In conjunction with high density lipoprotein and total serum cholesterol, a triglyceride determination provides valuable information for the assessment of coronary heart disease risk.It is done in fasting state.

High-density lipoprotein (HDL) cholesterol. This is sometimes called the ""good"" cholesterol because it helps carry away LDL cholesterol, thus keeping arteries open and blood flowing more freely.HDL cholesterol is inversely related to the risk for cardiovascular disease. It increases following regular exercise, moderate alcohol consumption and with oral estrogen therapy. Decreased levels are associated with obesity, stress, cigarette smoking and diabetes mellitus.

SERUM LDL The small dense LDL test can be used to determine cardiovascular risk in individuals with metabolic syndrome or established/progressing coronary artery disease, individuals with triglyceride levels between 70 and 140 mg/dL, as well as individuals with a diet high in trans-fat or carbohydrates. Elevated sdLDL levels are associated with metabolic syndrome and an 'atherogenic lipoprotein profile', and are a strong, independent predictor of cardiovascular disease. Elevated levels of LDL arise from multiple sources. A major factor is sedentary lifestyle with a diet high in saturated fat. Insulin-resistance and pre-diabetes have also been implicated, as has genetic predisposition. Measurement of sdLDL allows the clinician to get a more comprehensive picture of lipid risk factors and tailor treatment accordingly. Reducing LDL levels will reduce the risk of CVD and MI.

Non HDL Cholesterol - Adult treatment panel ATP III suggested the addition of Non-HDL Cholesterol as an indicator of all atherogenic lipoproteins (mainly LDL and VLDL). NICE guidelines recommend Non-HDL Cholesterol measurement before initiating lipid lowering therapy. It has also been shown to be a better marker of risk in both primary and secondary prevention studies.

Recommendations:

Results of Lipids should always be interpreted in conjunction with the patient's medical history, clinical presentation and other findings.

NON FASTING LIPID PROFILE includes Total Cholesterol, HDL Cholesterol and calculated non-HDL Cholesterol. It does not include triglycerides and may be best used in patients for whom fasting is difficult. LIVER FUNCTION PROFILE, SERUM-

LIVER FUNCTION PROFILE

Bilirubin is a yellowish pigment found in bile and is a breakdown product of normal heme catabolism. Bilirubin is excreted in bile and urine, and elevated levels may give yellow discoloration in jaundice. Elevated levels results from increased bilirubin production (eg, hemolysis and ineffective erythropoiesis), decreased bilirubin excretion (eg, obstruction and hepatitis), and abnormal bilirubin metabolism (eg, hereditary and neonatal jaundice). Conjugated (direct) bilirubin is elevated more than unconjugated (indirect) bilirubin in Viral hepatitis, Drug reactions, Alcoholic liver disease Conjugated (direct) bilirubin is also elevated more than unconjugated (indirect) bilirubin when there is some kind of blockage of the bile ducts like in Gallstones getting into the bile ducts, tumors &Scarring of the bile ducts. Increased unconjugated (indirect) bilirubin may be a result of Hemolytic or pernicious anemia, Transfusion reaction & a common metabolic condition termed Gilbert syndrome, due to low levels of the enzyme that attaches sugar molecules to bilirubin.

AST is an enzyme found in various parts of the body. AST is found in the liver, heart, skeletal muscle, kidneys, brain, and red blood cells, and it is commonly measured clinically as a marker for liver health. AST levels increase during chronic viral hepatitis, blockage of the bile duct, cirrhosis of the liver, liver cancer, kidney failure, hemolytic anemia, pancreatitis, hemochromatosis. AST levels may also increase after a heart attack or strenuous activity. ALT test measures the amount of this enzyme in the blood. ALT is found mainly in the liver, but also in smaller amounts in the kidneys, heart, muscles, and pancreas. It is commonly measured as a part of a diagnostic evaluation of hepatocellular injury, to determine liver health.AST levels increase during acute hepatitis, sometimes due to a viral infection, is chemia to the liver, chronic

hepatitis, obstruction of bile ducts, cirrhosis.

ALP is a protein found in almost all body tissues. Tissues with higher amounts of ALP include the liver, bile ducts and bone. Elevated ALP levels are seen in Biliary obstruction,







ACROFEMI HEALTHCARE LTD (MEDIWHEEL)

F-703, F-703, LADO SARAI, MEHRAULI SOUTH WEST DELHI

NEW DELHI 110030 DELHI INDIA 8800465156

S.K. Tower, Hari Niwas, LBS Marg

THANE, 400602 MAHARASHTRA, INDIA

Tel: 9111591115, Fax: CIN - U74899PB1995PLC045956

Email: customercare.thane@srl.in

PATIENT NAME: ARVIND PANDIT MALI

PATIENT ID:

ARVIM161278181

ACCESSION NO: 0181VC001353 AGE: 43 Years SEX: Male

RECEIVED: 30/03/2022 09:56 DRAWN: REPORTED: 01/04/2022 12:50

REFERRING DOCTOR: SFLF CLIENT PATIENT ID:

Test Report Status Results **Biological Reference Interval** Units <u>Final</u>

Osteoblastic bone tumors, osteomalacia, hepatitis, Hyperparathyroidism, Leukemia, Lymphoma, Paget's disease, Rickets, Sarcoidosis etc. Lower-than-normal ALP levels seen in Hypophosphatasia, Malnutrition, Protein deficiency, Wilson's disease. GGT is an enzyme found in cell membranes of many tissues mainly in the liver, kidney and pancreas. It is also found in other tissues including intestine, spleen, heart, brain and seminal vesicles. The highest concentration is in the kidney, but the liver is considered the source of normal enzyme activity. Serum GGT has been widely used as an index of liver dysfunction. Elevated serum GGT activity can be found in diseases of the liver, biliary system and pancreas. Conditions that increase serum GGT are obstructive liver disease, high alcohol consumption and use of enzyme-inducing drugs etc. Serum total protein, also known as total protein, is a biochemical test for measuring the total amount of protein in serum. Protein in the plasma is made up of albumin and globulin. Higher-than-normal levels may be due to: Chronic inflammation or infection, including HIV and hepatitis B or C, Multiple myeloma, Waldenstrom's disease. Lower-than-normal levels may be due to: Agammaglobulinemia, Bleeding (hemorrhage), Burns, Glomerulonephritis, Liver disease, Malabsorption, Malnutrition, Nephrotic syndrome, Protein-losing enteropathy etc. Human serum albumin is the most abundant protein in human blood plasma. It is produced in the liver. Albumin constitutes about half of the blood serum protein. Low blood albumin levels (hypoalbuminemia) can be caused by: Liver disease like cirrhosis of the liver, nephrotic syndrome, protein-losing enteropathy, Burns, hemodilution, increased vascular permeability or decreased lymphatic clearance,malnutrition and wasting etc SERUM BLOOD UREA NITROGEN-

Causes of Increased levels

Pre renal

• High protein diet, Increased protein catabolism, GI haemorrhage, Cortisol, Dehydration, CHF Renal

• Renal Failure

Post Renal

• Malignancy, Nephrolithiasis, Prostatism

Causes of decreased levels

Liver disease
SIADH.

CREATININE, SERUM-

Higher than normal level may be due to:

• Blockage in the urinary tract

- Kidney problems, such as kidney damage or failure, infection, or reduced blood flow
- Loss of body fluid (dehydration)
 Muscle problems, such as breakdown of muscle fibers
- Problems during pregnancy, such as seizures (eclampsia)), or high blood pressure caused by pregnancy (preeclampsia)

Lower than normal level may be due to:

- Myasthenia Gravis
- Muscular dystrophy URIC ACID, SERUM-

Causes of Increased levels

- Dietary

 High Protein Intake.
- Prolonged Fasting,
- Rapid weight loss.

Gout

Lesch nyhan syndrome.

Type 2 DM.

Metabolic syndrome.

Causes of decreased levels

- Low Zinc IntakeOCP's
- Multiple Sclerosis

Nutritional tips to manage increased Uric acid levels

- Drink plenty of fluidsLimit animal proteins
- High Fibre foods
- Vit C IntakeAntioxidant rich foods

TOTAL PROTEIN, SERUM-

Serum total protein, also known as total protein, is a biochemical test for measuring the total amount of protein in serum. Protein in the plasma is made up of albumin and

Higher-than-normal levels may be due to: Chronic inflammation or infection, including HIV and hepatitis B or C, Multiple myeloma, Waldenstrom's disease Lower-than-normal levels may be due to: Agammaglobulinemia, Bleeding (hemorrhage), Burns, Glomerulonephritis, Liver disease, Malabsorption, Malnutrition, Nephrotic syndrome. Protein-losing enteropathy etc. ALBUMIN, SERUM-

Human serum albumin is the most abundant protein in human blood plasma. It is produced in the liver. Albumin constitutes about half of the blood serum protein. Low blood albumin levels (hypoalbuminemia) can be caused by: Liver disease like cirrhosis of the liver, nephrotic syndrome, protein-losing enteropathy, Burns, hemodilution, increased vascular permeability or decreased lymphatic clearance,malnutrition and wasting etc. ELECTROLYTES (NA/K/CL), SERUM-







ACROFEMI HEALTHCARE LTD (MEDIWHEEL)

F-703, F-703, LADO SARAI, MEHRAULI SOUTH WEST DELHI

NEW DELHI 110030 DELHI INDIA 8800465156

SRL Ltd

S.K. Tower, Hari Niwas, LBS Marg

THANE, 400602 MAHARASHTRA, INDIA

Tel: 9111591115, Fax: CIN - U74899PB1995PLC045956

Email: customercare.thane@srl.in

PATIENT NAME: ARVIND PANDIT MALI

PATIENT ID:

ARVIM161278181

ACCESSION NO: 0181VC001353 AGE: 43 Years SEX: Male

DRAWN: RECEIVED: 30/03/2022 09:56 REPORTED: 01/04/2022 12:50

REFERRING DOCTOR: SFLF CLIENT PATIENT ID:

Test Report Status Results **Biological Reference Interval** Units <u>Final</u>

Sodium levels are Increased in dehydration, cushing's syndrome, aldosteronism & decreased in Addison's disease, hypopituitarism, liver disease. Hypokalemia (low K) is common in vomiting, diarrhea, alcoholism, folic acid deficiency and primary aldosteronism. Hyperkalemia may be seen in end-stage renal failure, hemolysis, trauma, Addison's disease, metabolic acidosis, acute starvation, dehydration, and with rapid K infusion. Chloride is increased in dehydration, renal tubular acidosis (hyperchloremia metabolic acidosis), acute renal failure, metabolic acidosis associated with prolonged diarrhea and loss of sodium bicarbonate, diabetes insipidus, adrenocortical hyperfuction, salicylate intoxication and with excessive infusion of isotonic saline or extremely high dietary intake of salt. Chloride is decreased in overhydration, chronic réspiratory acidosis, salt-losing nephritis, metabolic alkalosis, congestive heart failure, Addisonian crisis, certain types of metabolic acidosis, persistent gastric secretion and prolonged vomiting.

URINALYSIS-Routine urine analysis assists in screening and diagnosis of various metabolic, urological, kidney and liver disorders

Protein: Elevated proteins can be an early sign of kidney disease. Urinary protein excretion can also be temporarily elevated by strenuous exercise, orthostatic proteinuria, dehydration, urinary tract infections and acute illness with fever

Glucose: Uncontrolled diabetes mellitus can lead to presence of glucose in urine. Other causes include pregnancy, hormonal disturbances, liver disease and certain medications.

Ketones: Uncontrolled diabetes mellitus can lead to presence of ketones in urine. Ketones can also be seen in starvation, frequent vomiting, pregnancy and strenuous

Blood: Occult blood can occur in urine as intact erythrocytes or haemoglobin, which can occur in various urological, nephrological and bleeding disorders.

Leukocytes: An increase in leukocytes is an indication of inflammation in urinary tract or kidneys. Most common cause is bacterial urinary tract infection. Nitrite: Many bacteria give positive results when their number is high. Nitrite concentration during infection increases with length of time the urine specimen is retained in

bladder prior to collection. pH: The kidneys play an important role in maintaining acid base balance of the body. Conditions of the body producing acidosis/ alkalosis or ingestion of certain type of food can affect the pH of urine.

Specific gravity: Specific gravity gives an indication of how concentrated the urine is. Increased specific gravity is seen in conditions like dehydration, glycosuria and

proteinuria while decreased specific gravity is seen in excessive fluid intake, renal failure and diabetes insipidus. Bilirubin: In certain liver diseases such as biliary obstruction or hepatitis, bilirubin gets excreted in urine.

Urobilinogen: Positive results are seen in liver diseases like hepatitis and cirrhosis and in cases of hemolytic anemia
THYROID PANEL, SERUMTriiodothyronine T3, is a thyroid hormone. It affects almost every physiological process in the body, including growth, development, metabolism, body temperature, and heart rate. Production of T3 and its prohormone thyroxine (T4) is activated by thyroid-stimulating hormone (TSH), which is released from the pituitary gland. Elevated concentrations of T3, and T4 in the blood inhibit the production of TSH.

Thyroxine T4, Thyroxine's principal function is to stimulate the metabolism of all cells and tissues in the body. Excessive secretion of thyroxine in the body is hyperthyroidism, and deficient secretion is called hypothyroidism. Most of the thyroid hormone in blood is bound to transport proteins. Only a very small fraction of the

circulating hormone is free and biologically active.

In primary hypothyroidism, TSH levels are significantly elevated, while in secondary and tertiary hypothyroidism, TSH levels are low.

Below mentioned are the guidelines for Pregnancy related reference ranges for Total T4, TSH & Total T3

Levels in TOTAL T4 TSH3G TOTAL T3 (µg/dL) (µIU/mL) (ng/dL) Pregnancy 6.6 - 12.4 6.6 - 15.5 0.1 - 2.5 0.2 - 3.0 0.3 - 3.0 81 - 190 100 - 260 100 - 260 First Trimester 2nd Trimester 6.6 - 15.5 3rd Trimester

Below mentioned are the guidelines for age related reference ranges for T3 and T4. T3 $\,$ T4 $\,$

(ng/dL) (µg/dL) 1-3 day: 8.2 - 19.9 1 Week: 6.0 - 15.9 New Born: 75 - 260

NOTE: TSH concentrations in apparently normal euthyroid subjects are known to be highly skewed, with a strong tailed distribution towards higher TSH values. This is well

documented in the pediatric population including the infant age group.

Kindly note: Method specific reference ranges are appearing on the report under biological reference range.

Reference:

- 1. Burtis C.A., Ashwood E. R. Bruns D.E. Teitz textbook of Clinical Chemistry and Molecular Diagnostics, 4th Edition.
- 2. Gowenlock A.H. Varley's Practical Clinical Biochemistry, 6th Edition.
 3. Behrman R.E. Kilegman R.M., Jenson H. B. Nelson Text Book of Pediatrics, 17th Edition

ABO GROUP & RH TYPE, EDTA WHOLE BLOOD-

Blood group is identified by antigens and antibodies present in the blood. Antigens are protein molecules found on the surface of red blood cells. Antibodies are found in plasma. To determine blood group, red cells are mixed with different antibody solutions to give A,B,O or AB.

Disclaimer: "Please note, as the results of previous ABO and Rh group (Blood Group) for pregnant women are not available, please check with the patient records for availability of the same."

The test is performed by both forward as well as reverse grouping methods.

MEDICAL

THIS REPORT CARRIES THE SIGNATURE OF OUR LABORATORY DIRECTOR. THIS IS AN INVIOLABLE FEATURE OF OUR LAB MANAGEMENT SOFTWARE. HOWEVER, ALL EXAMINATIONS AND INVESTIGATIONS HAVE BEEN CONDUCTED BY OUR PANEL OF DOCTORS.







CLIENT'S NAME AND ADDRESS: ACROFEMI HEALTHCARE LTD (MEDIWHEEL) F-703, F-703, LADO SARAI, MEHRAULI SOUTH WEST DELHI

NEW DELHI 110030 DELHI INDIA 8800465156

S.K. Tower, Hari Niwas, LBS Marg

THANE, 400602 MAHARASHTRA, INDIA

Tel: 9111591115, Fax: CIN - U74899PB1995PLC045956

Email: customercare.thane@srl.in

PATIENT NAME: ARVIND PANDIT MALI

PATIENT ID:

ARVIM161278181

ACCESSION NO: 0181VC001353

AGE: 43 Years SEX: Male

REPORTED:

01/04/2022 12:50

DRAWN:

RECEIVED: 30/03/2022 09:56

CLIENT PATIENT ID:

Test Report Status

REFERRING DOCTOR: SELF

<u>Final</u>

Results

Units

MEDI WHEEL FULL BODY HEALTH CHECK UP ABOVE 40 MALE

ULTRASOUND ABDOMEN ULTRASOUND ABDOMEN GRADE I FATTY LIVER GALL BLADDER POLYP

End Of Report

Please visit www.srlworld.com for related Test Information for this accession

Dr.Priyal Chinchkhede

Phinchkhede

Consultant Pathologist

Dr. Ushma Wartikar **Consultant Pathologist** Dr. Sonali Praharaj ,MD

Pathologist



